Abstract: The disclosure provides a secondary battery, a battery pack, and an electronic device. The secondary battery includes a housing and an electrode assembly; the housing includes an end wall and a sidewall surrounding the end wall, the sidewall and the end wall are integrally formed by stretching; the electrode assembly is accommodated in the housing; wherein a wall thickness of the end wall is a, a wall thickness of the sidewall is b, 1<a/b<3, and the technical issue of battery performance degradation caused by uneven side pressure of the housing on the electrode assembly may be alleviated.

Abstract: A secondary battery includes a housing, an electrode assembly, an electrode terminal, and a sealing member. The housing includes an end wall and a side wall surrounding the end wall, and the end wall is provided with an electrode terminal hole. The electrode assembly is arranged in the housing. The electrode terminal passes through the end wall and is electrically connected to the electrode assembly. The sealing member is located between the electrode terminal and the end wall. A compression ratio w of the sealing member is in a range of: 20%?w?50%. The technical problem of lowered sealing performance of the sealing member between the electrode terminal and the housing under the influence of temperature rise is improved.

Abstract: Disclosed are an anti-CD40 antibody, an anti-PD-L1×CD40 bispecific antibody, and use thereof. The anti-CD40 antibody comprises a heavy chain variable region and a light chain variable region. The heavy chain variable region comprises the HCDR1, HCDR2 and HCDR3 in SEQ ID NO: 64. The light chain variable region comprises the LCDR1, LCDR2 and LCDR3 in SEQ ID NO: 65. The novel anti-CD40 agonistic antibody of the present invention can effectively regulate and control the activation of DC cells, has a stronger T cell activation effect while having low toxic and side effects, and is suitable for immunotherapy of tumors. The bispecific antibody of the present invention can maximize the anti-tumor drug effect, improve the selectivity of CD40 activation by means of PD-L1-dependent CD40 activation, and lower the toxic and side effects of the CD40 agonistic antibody.

Abstract: The present disclosure relates to antibodies that specifically binding to TL1A and uses thereof, in particular to antibodies that specifically bind to TL1A or antigen-binding fragments thereof, nucleic acids encoding the antibodies or antigen-binding fragments thereof, vectors containing the nucleic acids, and host cells containing the nucleic acids or the vectors. Pharmaceutical compositions comprising the antibodies as well as methods of treatment using the antibodies are also provided.

Abstract: A device is provided for unpackaging components encased between a first tape body and a second tape body of a sealed tape. The device includes a component collection device including a cavity for receiving components falling out of the sealed tape being de-taped. A de-taping device is attached to the component collection device. The de-taping device includes a support base held over the cavity, and a shaft on one side of the support base. The support base with the shaft is configured to enable one of the first tape body and the second tape body to be extendable around the shaft and the support base and to be pullable, such that the first tape body and the second tape body are separated and the components fall out of the sealed tape. The support base may include a through-hole configured for sealed tapes to pass through and to be held.

Abstract: Provided are an anti-TNF?/anti IL-17A natural antibody structure-like heterodimer form of a bispecific antibody and a preparation method therefor, wherein the antibody can bind two target molecules simultaneously, and can be used for treating complex diseases.

Abstract: A device is provided for unpackaging components encased between a first tape body and a second tape body of a sealed tape. The device includes a component collection device including a cavity for receiving components falling out of the sealed tape being de-taped. A de-taping device is attached to the component collection device. The de-taping device includes a support base held over the cavity, and a shaft on one side of the support base. The support base with the shaft is configured to enable one of the first tape body and the second tape body to be extendable around the shaft and the support base and to be pullable, such that the first tape body and the second tape body are separated and the components fall out of the sealed tape. The support base may include a through-hole configured for sealed tapes to pass through and to be held.

Abstract: A method for entity relations extraction including applying entity markers to a set of sentences included in a data bag to generate a token sequence for a subset of the set of sentences, the token sequence including a beginning position mark and an ending position mark of a corresponding sentence, as well as a front position mark and a rear position mark of at least one entity included in each of the subset of the set of sentences; using the generated token sequences of the set of sentences with a pre-trained language representation model to generate a sentence feature vector for each sentence included in the data bag; aggregating, in a data encoding module, the sentence feature vectors of the set of sentences into a bag encoding vector; and classifying data entity relations of the set of sentences included in the data bag through decoding and inferencing the bag encoding vector.

Abstract: The present invention provides an anti-PD-L1/anti-CD47 bispecific antibody and a preparation method therefor. The antibody has characteristics of a natural IgG, and is a highly stable heterodimeric form without heavy and light chain mismatching. The bispecific antibody can bind two target molecules at the same time and has a smaller side effect.

Abstract: Provided are an anti-PD-L1/anti-4-1BB natural antibody structure-like heterodimeric form bispecific antibody and a preparation thereof. Specifically, provided are an anti-PD-L1/anti-4-1BB bispecific antibody that has natural IgG features, that has no mismatch between heavy and light chains and that is in the form of a highly stable heterodimer, as well as a preparation method therefor. The bispecific antibody can simultaneously bind two target molecules and is more effective in treating complex diseases and has fewer side effects.

Abstract: An anti-PD-1/anti-VEGF natural antibody structure-like heterodimeric form bispecific antibody and preparation thereof. Provided are a highly stable, heterodimeric form anti-PD-1/anti-VEGF bispecific antibody having natural IgG characteristics and free of mismatched heavy and light chains and preparation method for the antibody. The bispecific antibody is capable of simultaneously binding with two target molecules and provides improved efficacy in treating a complicated disease.

Abstract: Provided are an anti-PD-1/anti-HER2 natural antibody structural heterodimeric bispecific antibody and a method of preparing the same. More particularly, provided are a highly stable heterodimeric anti-PD-1/anti-HER2 bispecific antibody having natural IgG characteristics without mismatch between a heavy chain and a light chain, and a method of preparing the same. The bispecific antibody may bind to two target molecules simultaneously and has excellent effects in treatment of a complex disease.

Abstract: Provided are an anti-PD-L1/anti-CD47 bispecific antibody that has natural IgG characteristics and is in a highly stable heterodimer form without the heavy chain and light chain being mismatched, and a preparation method therefor. Either the first Fc chain or second Fc chain of the bispecific antibody comprises amino acid substitutions at positions 366 and 399, and the other comprises amino acid substitutions at positions 351, 407 and 409.

Abstract: Provided are an anti-PD-L1/anti-PD-1 natural antibody structure-like heterodimeric bispecific antibody and a preparation thereof. In particular, provided are a highly stable heterodimeric anti-PD-L1/anti-PD-1 bispecific antibody with characteristics of a natural IgG and without mismatches heavy chain-light chain, and a preparation thereof. The bispecific antibody can bind to both target molecules and is more effective in treating a complex disease.

Abstract: The present invention provides a method for production of stable and highly specific heterodimeric immunoglobulin constructs, e.g., bispecific antibodies, retaining desirable properties of native IgG and lacking undesirable heavy chain-light chain mispairing, that can simultaneously bind two target molecules and are more potent in the treatment of complex diseases.

Abstract: The present disclosure provides a method of separating hematopoietic stem cells from umbilical cord blood, including the following steps: a hydroxyethyl starch solution is added into cord blood and mixed uniformly, then centrifuged to get an upper liquid layer and a lower erythrocyte layer; the liquid in the upper layer and the erythrocytes in the lower layer are centrifuged respectively; an upper plasma layer and a basal cell layer are obtained after the centrifugation of the upper liquid layer, the cells in the basal layer are resuspended; a superficial buffy-coat layer is obtained after the centrifugation of the erythrocytes, and the superficial buffy-coat layer is metered with the plasma in the upper layer, and then centrifuged to get a lower cell layer, which is precipitated to remove erythrocytes and then resuspended; the above resuspended cells are added into freezing medium, mixed uniformly and then stored in a liquid nitrogen tank.

Abstract: Provided are an anti-PD-1/anti-HER2 natural antibody structural heterodimeric bispecific antibody and a method of preparing the same. Specifically, provided are a highly stable anti-PD-1/anti-HER2 heterodimeric bispecific antibody having characteristics of a natural IgG and having no mismatched heavy chain and light chain, and a method of preparing the same. The bispecific antibody may bind to both of two kinds of target molecules, and thus may be more effective in treating complex diseases.

Abstract: Provided are an anti-TNF?/anti IL-17A natural antibody structure-like heterodimer form of a bispecific antibody and a preparation method therefor, wherein the antibody can bind two target molecules simultaneously, and can be used for treating complex diseases.

Abstract: An antibody specifically binding to PD-1 and a functional fragment thereof. The antibody or functional fragment thereof includes a PD-1 chimeric antibody and a functional fragment thereof, and a PD-1 humanized antibody and a functional fragment thereof.

Abstract: Provided are an anti-PD-L1/anti-CD47 bispecific antibody that has natural IgG characteristics and is in a highly stable heterodimer form without the heavy chain and light chain being mismatched, and a preparation method therefor. Either the first Fc chain or second Fc chain of the bispecific antibody comprises amino acid substitutions at positions 366 and 399, and the other comprises amino acid substitutions at positions 351, 407 and 409.